- 1. A generic substitution was dispensed.
- (UMLS (HL7) C1549557) =Idea or Concept =Substitution Status;
| - 51. age difference
- [index on studies in which age is an important variable or which deal with known or potential differences between two or more age classes. ( CSP )] (UMLS (CSP) C0699810) =Age Group ;
=aging;
=generation difference |
- 2. A1G4 anti-idiotype monoclonal antibody vaccine
- [An anti-idiotypic (anti-Id) rat monoclonal antibody (MoAb) that mimics the disialoganglioside GD2, a cancer-associated antigen present on melanoma, small cell lung cancer, sarcoma, neuroblastoma and other malignancies. GD2 is a highly expressed glycosphingolipid by melanoma and other neuroectodermal tumors with only minimal expression on normal tissues. Vaccination with anti-Id A1G4 MoAb may elicit cellular and humoral immune responses against GD2 expression tumor cells. ( NCI )] (UMLS (NCI) C0677670) =Pharmacologic Substance; Immunologic Factor ;
| - 52. age discrimination
- [ ] (UMLS (CSP) C0850364) =Social Behavior
|
- 3. A2G Mouse
- (UMLS (NCI) C1510677) =Mammal ;
| - 53. age eligibility
- [A person becomes eligible for a program based on age. Example: In the U.S., a person who is 65 years of age or older is eligible for Medicare. ( HL7V3.0 )] (UMLS (HL7) C1698001) =Finding ;
=CoverageEligibilityReason;
|
- 4. AG
- [A country in Northern Africa, bordering the Mediterranean Sea, between Morocco and Tunisia. (NCI) ( NCI )] (UMLS (NCI) C0002037) =Geographic Area
| - 54. age group
- [general term for grouping age group terms; do not index. ( CSP )] (UMLS (CSP) C0596048) =Age Group ;
=named group;
=gestational age;
Age categories;
animal age group;
|
- 5. AG 126
- (UMLS (NCI) C0526815) =Organic Chemical; Pharmacologic Substance
| - 55. age of onset
- [The age or period of life at which a disease or the initial symptoms or manifestations of a disease appear in an individual. ( MSH )] (UMLS (CSP) C0206132) =Quantitative Concept ;
|
- 6. AG 1295
- [A member of the Tyrphostin family of tyrosine kinase inhibitors that inhibits signal transduction through platelet-derived growth factor receptor and selectively attenuates smooth muscle cell growth. (NCI) ( NCI )] (UMLS (NCI) C0914052) Tyrphostin AG 1295;
=Organic Chemical; Pharmacologic Substance ;
| - 56. age patient qn calc
- [ Definition:Calculated age. ( HL7V3.0 )] (UMLS (HL7) C0944988) =Clinical Attribute ;
=ActCode;
|
- 7. AG 1296
- [A member of the tyrphostin family of tyrosine kinase inhibitors that selectively inhibits platelet-derived growth factor receptor protein. (NCI) ( NCI )] (UMLS (NCI) C0539578) =Organic Chemical; Pharmacologic Substance ;
| - 57. age patient qn definition
- [ Definition:General specification of age with no implied method of determination. ( HL7V3.0 )] (UMLS (HL7) C1698648) =Intellectual Product =ActCode;
|
- 8. AG 1478
- [A member of the tyrphostin family of tyrosine kinase inhibitors, that selectively inhibits epidermal growth factor. (NCI) ( NCI )] (UMLS (NCI) C0528985) =Organic Chemical; Pharmacologic Substance
| - 58. age patient qn est
- [ Definition:Estimated age. ( HL7V3.0 )] (UMLS (HL7) C0804404) =Clinical Attribute ;
=ActCode;
|
- 9. AG 1517
- [A quinazoline derivative that selectively inhibits EGFR kinase activity and suppresses the growth of psoriatic keratinocytes. ( NCI )] (UMLS (NCI) C0665630) =Organic Chemical; Pharmacologic Substance ;
| - 59. age patient qn reported
- [ Definition:Reported age. ( HL7V3.0 )] (UMLS (HL7) C0804405) =Clinical Attribute ;
=ActCode;
|
- 10. AG 1732
- [A tyrphostin compound inhibiting receptor autophosphorylation by inhibiting protein tyrosine kinase and is used to study receptor function. ( NCI )] (UMLS (NCI) C1510688) AG-1732;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance | - 60. age related bone loss
- [ ] (UMLS (CSP) C0001787) =Disease or Syndrome
|
- 11. AG 18
- [A broad spectrum protein tyrosine kinase inhibitor that inhibits epidermal growth factor receptor, GTPase activity of transducin, aldosterone secretion in response to Angiotensin II, and suppresses the activation of MAP kinases. (NCI) ( NCI )] (UMLS (NCI) C0638102) =Organic Chemical; Pharmacologic Substance
| - 61. age related macular degeneration
- [ ] (UMLS (CSP) C0242383) =Disease or Syndrome ;
|
- 12. AG 183
- (UMLS (NCI) C0101807) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
| - 62. Age, in Months
- [The length of a person's life, stated in months since birth. ( NCI )] (UMLS (NCI) C1510828) Age-Months;
=Organism Attribute |
- 13. AG 213
- (UMLS (NCI) C0165383) =Organic Chemical; Pharmacologic Substance
| - 63. Age, in Years
- [The length of a person's life, stated in years since birth. ( NCI )] (UMLS (NCI) C1510829) Age-Years;
=Temporal Concept |
- 14. AG 30
- [A potent protein tyrosine kinase inhibitor that exhibits greater specificity for c-ErbB oncoprotein. (NCI) ( NCI )] (UMLS (NCI) C0378866) =Amino Acid, Peptide, or Protein; Pharmacologic Substance
| - 64. Age-adjusted PSA
- [There is a natural increase in PSA level with increasing age. Thus, the normal PSA level changes with age. Age-adjusted PSA establishes normal values in 10-year age blocks. (from Cancer Information Service) ( NCI )] (UMLS (NCI) C1510830) =Diagnostic Procedure
|
- 15. AG 490
- (UMLS (NCI) C0381241) =Organic Chemical; Pharmacologic Substance ;
| - 65. Aged 65 and Over
- [An age group comprised by people 65 years of age and older. (NCI) ( NCI )] (UMLS (NCI) C0001792) =Population Group
|
- 16. AG 494
- (UMLS (NCI) C0664362) =Organic Chemical; Pharmacologic Substance ;
| - 66. Agencies
- [A non-facility provider that renders outpatient outreach services that are not provided at a specific location. The licensure or registration is assigned to the agency rather than to the individual practitioners as would be the case in a group practice. ( HL7V3.0 )] (UMLS (HL7) C1556110) =Intellectual Product =NUCC Health Care Provider Taxonomy;
=Case Management;
Day Training, Developmentally Disabled Services;
Home Health;
Home Infusion;
Hospice Care, Community Based;
Nursing Care;
Public Health or Welfare;
Voluntary or Charitable;
|
- 17. AG 555
- (UMLS (NCI) C0253197) =Organic Chemical; Pharmacologic Substance
| - 67. Agencies; Agency; Case Management
- (UMLS (HL7) C1551243) =Health Care Related Organization ;
=HealthcareProviderTaxonomyHIPAA;
|
- 18. AG 556
- (UMLS (NCI) C0388640) =Organic Chemical; Pharmacologic Substance ;
| - 68. Agencies; Agency; Home Health
- (UMLS (HL7) C1551244) =Health Care Related Organization ;
=HealthcareProviderTaxonomyHIPAA;
|
- 19. AG 825
- [A member of the tyrphostin family of tyrosine kinase inhibitors, which selectively inhibits HER2. (NCI) ( NCI )] (UMLS (NCI) C0386977) =Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
| - 69. Agencies; Agency; Home Infusion
- (UMLS (HL7) C1551245) =Health Care Related Organization ;
=HealthcareProviderTaxonomyHIPAA;
|
- 20. AG 879
- [A compound that selectively inhibits protein tyrosine kinase and nerve growth factor-dependent tyrosine phosphorylation. (NCI) ( NCI )] (UMLS (NCI) C0215862) =Organic Chemical; Pharmacologic Substance ;
| - 70. Agencies; Agency; Hospice Care, Community Based
- (UMLS (HL7) C1551246) =Health Care Related Organization ;
=HealthcareProviderTaxonomyHIPAA;
|
- 21. AG 957
- [A member of the tyrphostin family of tyrosine kinase inhibitors that selectively inhibits human p210 tyrosine kinase activity. (NCI) ( NCI )] (UMLS (NCI) C0536972) =Organic Chemical ;
| - 71. Agencies; Agency; Nursing Care
- (UMLS (HL7) C1551247) =Health Care Related Organization ;
=HealthcareProviderTaxonomyHIPAA;
|
- 22. AG 99
- (UMLS (NCI) C0662831) =Organic Chemical; Pharmacologic Substance ;
| - 72. Agencies; Agency; Public Health or Welfare
- (UMLS (HL7) C1551248) =Health Care Related Organization ;
=HealthcareProviderTaxonomyHIPAA;
|
- 23. Ag element
- [white, soft, malleable and ductile metal, symbol Ag, atomic number 47; compounds are extensively used in medicine and metallic silver is employed in surgery, dental prostheses, and the manufacture of instruments. ( CSP )] (UMLS (CSP) C0037125) =Biomedical or Dental Material; Biologically Active Substance; Hazardous or Poisonous Substance; Element, Ion, or Isotope =heavy metal;
| - 73. Agencies; Agency; Voluntary or Charitable
- (UMLS (HL7) C1551249) =Health Care Related Organization ;
=HealthcareProviderTaxonomyHIPAA;
|
- 24. AG-858
- [A recombinant cancer vaccine made with tumor-derived heat shock protein 70 (HSP70) peptide complexes. HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing. Tumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. (NCI04) ( NCI )] (UMLS (NCI) C1328058) Autologous Heat-Shock Protein 70 Peptide Vaccine AG-858;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 74. Agency for Health Care Policy and Research
- [The Agency for Healthcare Research and Quality (AHRQ), a component of the US Department of Health and Human Services, Public Health Service, is the Federal Government's focal point for research of the availability, quality, and costs of health care services; and ways to improve the effectiveness and appropriateness of clinical practice, including the prevention of diseases. AHRQ uses mechanisms of grants, cooperative agreements, and contracts to carry out research projects, demonstrations, evaluations, and knowledge dissemination. Nearly 80 percent of AHRQ's budget is awarded as grants and contracts to researchers at universities and other research institutions across the country. AHRQ was formerly known as the Agency for Health Care Policy and Research (AHCPR). ( NCI )] (UMLS (NCI) C0080268) =Health Care Related Organization ;
|
- 25. AG-858/Imatinib Mesylate
- (UMLS (NCI) C1328059) =Therapeutic or Preventive Procedure; ;
| - 75. agenerase
- [ ] (UMLS (CSP) C0754187) =Organic Chemical; Pharmacologic Substance
|
- 26. AG-EE 623 ZW
- (UMLS (NCI) C0287495) =Organic Chemical; Pharmacologic Substance ;
| - 76. AGENESIS OF LUNG
- [ ] (UMLS (ICD9CM) C0438699) =Congenital Abnormality
|
- 27. ag/pg
- [A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit. ( NCI )] (UMLS (NCI) C1300559) Attogram per Picogram;
Femtogram per Nanogram;
fg/ng;
mcg/g;
mg/kg;
Microgram per Gram;
Milligram per Kilogram;
Nanogram per Milligram;
ng/mg;
pg/mcg;
pg/ug;
Picogram per Microgram;
yg/ag;
Yoctogram per Attogram;
Zeptogram per Femtogram;
zg/fg =Quantitative Concept | - 77. agent
- [An entity (player) that acts or is authorized to act on behalf of another entity (scoper). ( HL7V3.0 )] (UMLS (HL7) C1551364) =Group =RoleClassRelationshipFormal;
=guardian;
assigned entity |
- 28. AG013736
- [An orally bioavailable tyrosine kinase inhibitor. AG-013736 inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352181&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=352181&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C38718" NCI Thesaurus) ( PDQ )] (UMLS (NCI) C1328149) AG-013736 =Organic Chemical; Pharmacologic Substance
| - 78. Agent
- [An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. ( NCI )] (UMLS (NCI) C0450442) =Chemical Viewed Functionally ;
|
- 29. AG2
- [Encoded by human AGR2 Gene, soluble Anterior Gradient 2 Homologue Protein is 47% identical to the cement gland anterior gradient protein (Xenopus laevis) and 91% identical to the mouse protein. Strongest expression is seen in the lung; weaker expression in the pancreas and other tissues. Strong expression is also detected in trachea, stomach, colon, prostate, and small intestine. (from OMIM, and NCI) ( NCI )] (UMLS (NCI) C1332035) AGR2;
AGR2 Protein;
Anterior Gradient 2 Homolog;
GOB-4;
HAG-2;
Secreted Cement Gland Homolog;
XAG-2 =Amino Acid, Peptide, or Protein; Biologically Active Substance | - 79. Agent
- [An active natural, synthetic or semi-synthetic ingredient including endogenous body substance that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient (21 CFR 314.3(b)). ( NCI )] (UMLS (NCI) C1254351) Drug;
Pharmaceutical Agent;
Pharmaceuticals;
Pharmacologic Agent;
Pharmacologic Substance;
Pharmacological Substance =Pharmacologic Substance ;
|
- 30. AG2037
- [A substance that is being studied as a treatment for cancer. It belongs to the family of drugs called glycinamide ribonucleotide formyl transferase inhibitors. ( NCI )] (UMLS (NCI) C0935874) =Organic Chemical; Pharmacologic Substance
| - 80. Agent for a foreign manufacturer
- (UMLS (HL7) C1548598) =Idea or Concept =Facility type;
|
- 31. AG3340/Carboplatin/Paclitaxel
- (UMLS (NCI) C0678060) =Therapeutic or Preventive Procedure ;
| - 81. Agents of Opportunistic Infection
- [Infectious agents, which while normally present but remaining benign under the control of the immune system, become virulent and pathogenic in immune-compromised hosts (i.e when they get the opportunity to become infectious). ( NCI )] (UMLS (NCI) C1510832) =Organism
|
- 32. AG3340/DHAD/PRED
- (UMLS (NCI) C0678061) =Therapeutic or Preventive Procedure ;
| - 82. Agents primarily acting on the smooth and skeletal muscles and respiratory system causing adverse effects in therapeutic use
- [ ] (UMLS (ICD9CM) C0261903) =Injury or Poisoning
|
- 33. AG337
- (UMLS (NCI) C0281733) =Organic Chemical; Pharmacologic Substance ;
| - 83. Agents primarily affecting blood constituents causing adverse effects in therapeutic use
- [ ] (UMLS (ICD9CM) C0261803) =Injury or Poisoning
|
- 34. AG337/CDDP
- (UMLS (NCI) C0338311) =Therapeutic or Preventive Procedure ;
| - 84. Agents primarily affecting skin and mucous membrane, ophthalmological, otorhinolaryngological, and dental drugs causing adverse effects in therapeutic use
- [ ] (UMLS (ICD9CM) C0261913) =Injury or Poisoning
|
- 35. Against
- (UMLS (NCI) C0521124) =Qualitative Concept
| - 85. Agents primarily affecting the cardiovascular system causing adverse effects in therapeutic use
- (UMLS (ICD9CM) C1533672) =Injury or Poisoning ;
|
- 36. agammaglobulinemia
- [An immunologic deficiency state characterized by an extremely low level of generally all classes of gamma-globulin in the blood. ( MSH )] (UMLS (CSP) C0001768) =Disease or Syndrome ;
| - 86. Agents, infective
- (UMLS (NCI) C0450254) =Organism ;
|
- 37. aganglionic megacolon
- [abnormally large or dilated colon due to congenital absence of myenteric ganglion cells in a distal segment of the large bowel; resultant loss of motor function in this segment causes massive hypertrophic dilatation of the normal proximal colon; condition appears soon after birth; called also Hirschsprung's disease, aganglionic megacolon and pelvirectal achalasia. ( CSP )] (UMLS (CSP) C0019569) =Congenital Abnormality ;
=colon disorder;
Megacolon;
ANOM DIGESTIVE SYST NOS;
congenital gastrointestinal disorder | - 87. ageusia
- [Complete or severe loss of the subjective sense of taste, frequently accompanied by OLFACTION DISORDERS. ( MSH )] (UMLS (CSP) C0001800) =Sign or Symptom
|
- 38. Agaorse gel electrophoresis
- [A type of gel electrophoresis used in molecular biology to separate DNA strands by size using electrophoretic filtration with agarose as the support medium. Also used to separate proteins, lipoproteins, nucleic acids, and other substances. ( NCI )] (UMLS (HL7) C0013856) =Laboratory Procedure ;
=ObservationMethod;
| - 88. Agglutination
- [Agglutination ( HL7V3.0 )] (UMLS (HL7) C1551405) =Laboratory Procedure =ObservationMethod;
|
- 39. Agar Gel Immunodiffusion
- [Diffusion, Agar Gel Immunodiffusion ( HL7V3.0 )] (UMLS (HL7) C1553126) =Laboratory Procedure =ObservationMethod;
| - 89. agglutination reaction
- [mixing of antibodies with their corresponding antigens on the surface of large, easily sedimented particles such as animal cells, erythrocytes, or bacteria; the antibodies cross-link the particles, forming visible clumps. ( CSP )] (UMLS (CSP) C0001802) =Laboratory Procedure
|
- 40. Agar screen
- (UMLS (HL7) C1699544) =Laboratory Procedure =Susceptibility Testing;
| - 90. agglutinin
- [antibody or other substance that reacts with surface antigens of particles, such as red cells and bacteria, to agglutinate them. ( CSP )] (UMLS (CSP) C0001804) =Immunologic Factor
|
- 41. Agaricales
- [extensive order of basidiomycetous fungi whose fruiting bodies are commonly call mushrooms. ( CSP )] (UMLS (CSP) C0001774) =Fungus
| - 91. Aggravated Acne
- (UMLS (NCI) C0852967) =Finding
|
- 42. Agdaagux Tribe of King Cove
- (UMLS (HL7) C1550794) =Population Group =NativeEntityAlaska;
| - 92. Aggravated Arthritis
- (UMLS (NCI) C0235889) =Disease or Syndrome
|
- 43. Age
- [How long something has existed; elapsed time since birth. ( NCI )] (UMLS (NCI) C0001779) =Organism Attribute
| - 93. Aggravated Colitis
- (UMLS (NCI) C0852920) =Disease or Syndrome
|
- 44. Age Alert
- [Proposed therapy may be inappropriate or contraindicated due to patient age ( HL7V3.0 )] (UMLS (HL7) C1553537) =Intellectual Product =Observation Alert;
=High Dose for Age Alert;
Low Dose for Age Alert | - 94. Aggravated Epilepsy
- (UMLS (NCI) C0852977) =Disease or Syndrome
|
- 45. age associated immune deficiency
- [ ] (UMLS (CSP) C0597743) =Disease or Syndrome ;
| - 95. Aggravated Granuloma Annulare
- (UMLS (NCI) C0856139) =Finding
|
- 46. Age at First Full-Term Pregnancy
- [The age at which a woman gave birth to her first live child. ( NCI )] (UMLS (NCI) C1510831) Age at First Live Birth;
=Clinical Attribute | - 96. Aggravated Malignant Neoplasm
- (UMLS (NCI) C0236022) =Neoplastic Process
|
- 47. age at marriage
- [the age at which marriage takes place; typically indexed for epidemiologic research grants. ( CSP )] (UMLS (CSP) C0024842) =Quantitative Concept ;
=Age categories;
| - 97. Aggravated Neurofibromatosis
- (UMLS (NCI) C0235814) =Neoplastic Process
|
- 48. Age at Menarche
- [Age of first menstruation. A risk factor for breast cancer ( NCI )] (UMLS (NCI) C1314691) =Finding
| - 98. aggrecan
- [Large HYALURONAN-containing proteoglycans found in articular cartilage (CARTILAGE, ARTICULAR). They form into aggregates that provide tissues with the capacity to resist high compressive and tensile forces. ( MSH )] (UMLS (CSP) C0081487) =Amino Acid, Peptide, or Protein; Biologically Active Substance
|
- 49. age at onset of adverse event
- [ Definition:Age at onset of associated adverse event; no implied method of determination. ( HL7V3.0 )] (UMLS (HL7) C1115096) =Organism Attribute ;
=ActCode;
| - 99. Aggregates of Poorly Differentiated Neuroepithelial Cells Present
- (UMLS (NCI) C1510833) =Finding
|
- 50. age at pregnancy
- [the age at which pregnancy takes place; for indexing epidemiology and teenage pregnancies. ( CSP )] (UMLS (CSP) C0024915) =Temporal Concept =Age categories;
pregnancy | - 100. Aggregation
- [A process by which particles collect to form a cohesive mass or cluster. The resulting structure is called an aggregate. ( NCI )] (UMLS (NCI) C0332621) =Functional Concept
|
home
